## Page 1

Article
®
Effects of Zembrin (Sceletium tortuosum) Supplementation
on Mood, Soreness, and Performance Following Unaccustomed
Resistance Exercise: A Pilot Study
AngelaR.Berry†,HaleyN.Langley†,RebeccaR.Rogers ,CourteneyL.Benjamin,TylerD.Williams
andChristopherG.Ballmann*,‡
DepartmentofKinesiology,SamfordUniversity,Birmingham,AL35226,USA;aberry3@samford.edu(A.R.B.);
hlangley@samford.edu(H.N.L.);rrogers1@samford.edu(R.R.R.);cbenjami@samford.edu(C.L.B.);
twilli11@samford.edu(T.D.W.)
* Correspondence:cballman@samford.edu
† Authorsequallycontributedtothework.
‡ FACSM(FellowoftheAmericanCollegeofSportsMedicine).
Abstract:ThepurposeofthisstudywastoinvestigateacuteZembrin®(Sceletiumtortuosum)supple-
mentationonmusclesoreness,markersofmuscledamage,mood,andexerciseperformancefollowing
unaccustomedresistanceexercise.Untrainedfemales(n=16)weredividedintotwogroupswitha
(cid:1)(cid:2)(cid:3)(cid:1)(cid:4)(cid:5)(cid:6)(cid:7)(cid:8)(cid:1)
differentthree-daytreatmentregimen:(1)placebo(PL)and(2)Zembrin®(ZEM).Duringtheinitial
(cid:1)(cid:2)(cid:3)(cid:4)(cid:5)(cid:6)(cid:7)
visit,baselineperceivedsoreness,rangeofmotion(ROM),moodstate(profileofmoodstates(POMS)
Citation: Berry,A.R.;Langley,H.N.; questionnaire),andplasmalactatedehydrogenaseconcentrations(LDH)weremeasuredfollowedby
Rogers,R.R.;Benjamin,C.L.; theperformanceofaneccentricbicepcurlprotocolwiththeirnon-dominantarm.Thetotalrepetitions
Williams,T.D.;Ballmann,C.G.Effects andrateofperceivedexertion(RPE)wererecordedthroughouttheexercise.Theparticipantsthen
ofZembrin®(Sceletiumtortuosum) supplementedwiththecorrespondingtreatmentimmediatelyfollowing,thesubsequentday,and
SupplementationonMood,Soreness, 30minpriortocompletinga48hfollow-upvisit. Forthe48hvisit,allprocedureswererepeated
andPerformanceFollowing andcomparisonsweredrawnforperceivedsoreness,ROM,LDH,moodscores,totalrepetitions,
UnaccustomedResistanceExercise:A
andRPE.Thefindingsindicatethatshort-termZEMsupplementationresultedinlowerperceived
PilotStudy.Nutraceuticals2021,1,
soreness(p=0.020)andagreaterpreservationofROM(p=0.028)at48hversusthePLgroup.Mood
2–11. https://doi.org/10.3390/
worsenedfromthebaselineto48hregardlessofthetreatment(p=0.043)butthedecrementswere
nutraceuticals1010002
exacerbatedinthePLgroupcomparedwiththeZEMgroup(p<0.001).LDHlevels(p=0.019)and
RPE(p=0.008)werehigherandtotalrepetitionswerelower(p<0.001)at48hirrespectiveofthe
AcademicEditor:HerbertRyan
treatment.Althoughshort-termdietaryenrichmentwithZEMdidnotaltertheexerciseperformance
Marini
orbiomarkersofmuscledamage,thecurrentresultssuggestZEMsupplementationmaybeeffective
Received:25May2021 inreducingthemarkersofsorenessandpreservemoodfollowingunaccustomedeccentricexercise.
Accepted:2September2021
Published:16September2021 Keywords: range of motion; delayed onset muscle soreness; lactate dehydrogenase; profile of
moodstates
Publisher’sNote:MDPIstaysneutral
withregardtojurisdictionalclaimsin
publishedmapsandinstitutionalaffil-
iations. 1. Introduction
Sceletiumtortuosum(soldasastandardizedextractunderthenameZembrin®(ZEM))
isasucculentplantnativetotheSouthAfricanregion[1]. Intraditionalfolkmedicine,
leavesfromtheplanthavebeenchewedorusedinteasandimplicatedintheamelioration
Copyright: © 2021 by the authors. ofthirst,stavinghunger,anddecreasingfatigue[2]. Asoflate,ZEMhasbeenidentifiedas
Licensee MDPI, Basel, Switzerland. apromisingnutraceuticalwithpotentanxiolyticandanti-depressantactions[3,4]. These
This article is an open access article actions are likely manifested through high mesembrine alkaloid concentrations within
distributed under the terms and ZEM,whichhavebeenreportedtoaltercentralnervoussystemactivity[5]. Highlevelsof
conditionsoftheCreativeCommons anxietyandnegativeeffectshavebeensuggestedtoinducehyperalgesiaduringandafter
Attribution(CCBY)license(https:// exerciseaswellasdiminishingexerciseperformance[6,7]. Thus,identifyingtherapeutic
creativecommons.org/licenses/by/
strategiestocombatanxietyandmooddisturbancesduringandafterintenseexerciseare
4.0/).
Nutraceuticals2021,1,2–11.https://doi.org/10.3390/nutraceuticals1010002 https://www.mdpi.com/journal/nutraceuticals

## Page 2

Nutraceuticals2021,1 3
neededfortrainingandcompetitionineffortstoachievepeakperformance. However,the
effectsofZEMonexerciseperformanceandsorenessremainlargelyunclear.
Althoughthephysiologicalmechanismsfortheanxiolyticandmood-enhancingac-
tionsofZEMhavenotbeenfullyelucidated,multiplestudieshavereportedunderpinning
mechanisms to be the inhibition of phosphodiesterase-4 (PDE-4) and the blockade of
5-hydoxytryptamine(5HT)reuptake[3,8]. PreviousinvestigationshaveshownthatPDE-
4 inhibition results in increased cyclic-adenosine monophosphate (cAMP) signaling in
neuraltissue,therebyincreasingcellularsignaltransduction[9,10]. Bolsteringthis,psy-
chologicaldisorders,suchasdepression,havebeenshowntohavediminishedneuronal
cAMP signaling[11]. ZEM has been shown by multiple groups to be a strong PDE-4
inhibitor[8,12]. Forexample,Harveyetal. reportedthatZEMpotentlyinhibitedhuman
myeloidcell-derivedPDE-4activity[8]. 5HTreuptakeandtransporthasalsobeenshown
tobebluntedbyZEMtreatment[8,13]. Coetzeeetal. showedthatmesembrinealkaloids,
derivedfromSceletiumtortuosum,resultedinareduced5HTtransporterproteinexpression
inhumanastrocyteandmurinehippocampalcells[13]. Ofparticularimportance, 5HT
reuptakeinhibitorsarecommonlyusedinthepharmacologicaltreatmentofanxietyand
mooddisorders[14]. Moreover,thesynergisticablationof5HTreuptakeandPDE-4ac-
tivitymayprovideagreaterreliefofdepressivesymptoms,suggestingthattheactionsof
ZEMmaybeoptimizedthroughapleiotropicneuromodulation[15]. Reportsofanalgesic
andanti-inflammatoryactionshavealsobeenreportedwithZEMtreatment[16]. Bennet
etal. showedSceletiumtortuosumextractsbluntcytokinereleaseandmayprotectagainst
low levels of systemic inflammation [16]. Furthermore, rodents treated with alkaloids
fromZEMshoweddecreasednociceptivepainresponsessimilartoopioidcompounds,
indicatingastronganalgesicefficacyfromZEM[17]. Altogether,ZEMappearstobean
effectivenutraceuticalwithmulti-facetedactionsthroughthemodulationofmood,anxiety,
pain,andpossiblyinflammation. However,translationalstudiestohumansarelimited,
especiallyinthecontextofexercise,leavingtheneedforfurtherstudy.
InvestigationsofZEMtreatmentinhumanshavebeenprimarilystudiedinthecon-
textofanxietyandmood[3,4,18]. Terburgetal. showedthatZEMtreatmentdecreased
anxiety-relatedamygdalaactivationandmaydiminishthreatresponsivitybyamygdala-
hypothalamusdecoupling[3]. Improvementsinmoodandsleeppatterns,andreductions
inanxiety,havealsobeenreportedinyounghealthyadults[4,18].Weareonlyawareofone
investigationstudyinghowZEMsupplementationinfluencesresponsestophysicalexer-
cise. Recently,Hoffmanetal. demonstratedthat8daysofZEMsupplementationimproved
thecomplexreactiontimeandphysicaltaskperformancewithahighcognitiveload[19].
However,moodwasminimallyaffected(albeitallparticipantswereyoungandhealthy)
andnostimuluswasprovidedtoaltertheemotionalstate. Studiesfromourlabandothers
have suggested a role for anxiety and negative effects on the exacerbation of pain and
soreness,andreductionsinsubsequentperformancefollowingintenseexercise[20,21]. As
themaintenanceofmoodandexerciseperformanceareimportantinoptimizinglong-term
trainingandathleticperformance[22],identifyingnaturalremediesthatmayserveasa
panaceaforunderlyingnegativesymptomsafterintenseexerciseishighlydesirable. To
date,noinvestigationshavestudiedhowZEMmayinfluencesorenessandperformance
followingintenseexercise. Thus,thepurposeofthisstudywastoprovideapreliminary
investigationintotheeffectsofacuteZEM(Sceletiumtortuosum)supplementationonthe
markersofmusclesoreness/damage,mood,andexerciseperformancefollowingunaccus-
tomedresistanceexercise. WehypothesizedthatZEMtreatmentwouldattenuatemuscle
soreness/damageandimprovemood,therebypreservingexerciseperformance48hafter
intenseeccentricexercise.
2. MaterialsandMethods
2.1. StudyDesign
Aconveniencesampleofnon-resistance-trainedfemales(n=16)wererandomlyas-
signedintooneoftwogroups,(1)Zembrin(ZEM;Sceletiumtortuosum;n=8)and(2)placebo

## Page 3

Nutraceuticals2021,1 4
(PL;gluten-freecornstarch;n=8),inadouble-blinded,between-groupsstudydesign. Each
participantcompletedtwotrialseachseparatedby48h. Duringthefirstbaselinevisit,the
participantscompletedbaselineperceivedsoreness,rangeofmotion(ROM),andplasma
collectionforlactatedehydrogenasemeasurements. Forthesubsequentunaccustomed
resistanceexercise,theparticipantscompletedaneccentricbicepcurldescendingpyramid
whilethecompletedrepetitionsandtherateofperceivedexertion(RPE)wererecorded.
Anabbreviatedprofileofmoodstate(POMS)questionnairewasalsoadministeredbefore
andafterexercise. TheparticipantsthensupplementedwithZembrinoraplacebountil
thefollow-upvisit48hlater. Allmeasurementswerethenrepeatedidenticaltothefirst
baselinevisit. Comparisonsforallmeasurementsweremadebetweenthetimepointsof
datacollectionandtreatments.
2.2. Participants
Aconveniencesampleofhealthy,non-resistance-trainedfemales(n=16;age=21.0
year±1.6;height=164.0cm±6.1;bodymass=64.9kg±15.9)wererecruitedtoparticipate
inthisstudy. Non-resistance-trainedwasdefinedasparticipatinginstrengthtrainingno
morethanonetimeperweek[20,23]. Theexclusioncriteriaincluded: upperbodyinjuries
withinthepastsixmonths,acurrentdiseaseordiagnosisthatlimitedtheexercisecapacity,
adiagnosiswithamooddisorder,oracurrenttherapywithanti-depressantoranti-anxiety
medication. Toscreenforthesuitabilityofexercise,eachparticipantcompletedaphysical
activityreadinessquestionnaire(PAR-Q)[23].Beforeeachvisit,theparticipantswereasked
torefrainfromvigorousactivity24hpriorandfromconsumingcaffeine,nicotine,and
alcohol12hprior[24]. Theparticipantswereaskedtomaintaintheirnormalsleepand
dietaryroutinespriortoeachvisit.
2.3. Supplementation
Theparticipantsunderwentashort-termsupplementationregimenwitheitherZEM
(Nutricost,N.Vineyard,UT,USA)orPL(gluten-freecornstarch). Theparticipantsingested
asingledoseof25mg/dayoverthreedaysimmediatelyfollowingexerciseonthebaseline
visit,24hpost-exercise,and30minpriortoreturningfortheir48hvisit[5]. Gluten-free
cornstarchwasencapsulatedinasize“00”gelatincapsuleandmatchedinappearanceto
theZEMtreatment[20,24]. Alltreatmentsweredistributedinadouble-blindedmanner
wherebyanindependentresearcherorganizednon-identifiableopaquebagscontaining
eachtreatment. Toensurecompliance,theemptybagswerereturnedbytheparticipants
andrecorded. Noparticipantsreportedanysideeffectsfromthesupplementationthrough-
outtheinvestigation.
2.4. MuscleDamageBiomarker(PlasmaLactateDehydrogenaseActivity)
Approximately500–600µLofcapillarybloodwascollectedviaafingerprick. Briefly,
a 17-gauge 2.0 mm depth disposable blade lancet was used to induce bleeding on the
medialendofthefourthfinger. Usingagentlemassagingtechnique,bloodwascollected
viaacapillaryactionintolithium-heparincoatedmicrovette® tubes(SARSTEDT,Newton,
NC,USA).Thewholebloodwasthencentrifugedat10,000rpmfor10min. Theplasma
wasdecantedandstoredat−80◦Cuntilthebiochemicalanalysis,whichwascompleted
followingtheconclusionofthedatacollection. ThetotalLDHactivitywasdetermineusing
acommerciallyavailablecolorimetricplateassay(Elabscience,Houston,TX,USA)[25,26].
Allsampleswereanalyzedinduplicateandaccordingtothemanufacturer’sinstructions.
2.5. Procedures
Upon arrival for the first baseline visit, height and weight were recorded. The
participants then completed an abbreviated POMS questionnaire to assess their over-
allmood[27,28]. Followingthis,thebaselineelbowROMandperceivedsorenessofthe
bicepbrachiionthenon-dominantarmweremeasured. ForROM,theactiveflexionand
extensionweremeasuredwhileseatedusingagoniometer(EliteMedicalInstrumentsInc.,

## Page 4

Nutraceuticals2021,1 5
Anaheim,CA,USA)placedproximallywiththeheadofthehumerusanddistallywiththe
radialstyloid[20]. Theparticipantswereinstructedtoextendandflextheirarmasmuchas
possibleuntilthepointofsubjectivediscomfortandROMwascalculatedbysubtractingthe
degreeofextensionfromflexion[20]. Perceivedsorenesswasobtainedusinganalgometer
and pain visual analog scale. A bolster was placed behind the elbow with the arm at
fullextensionandanalgometer(Wagnerinstrument,Greenwich,CT,USA)waspressed
(40N)intothemid-pointofthemusclebellyofthebicepsbrachii[20]. Duringthis,the
participantsthenratedtheirpainonascaleof1(nopain)to10(worstpainpossible). A
capillary blood sample was then taken as previously described. Following all baseline
measurements,theparticipantscompletedadescendingeccentricbicepcurlpyramid. As
previously described by Allen et al. [29], starting at full elbow flexion, the participants
lowereda11.34kg(25lb)dumbbellwiththeirnon-dominantarmover3stothepaceofa
metronomesetto60bpm.Afterafullelbowextensionwasreached,theresearchersassisted
theparticipanttoreturnthedumbbelltothestartingposition. Theparticipantscompleted
asmanyrepetitionsaspossibleuntilvolitionalfatigueortheycouldnolongerkeeppace
withthemetronome. Thiswasrepeatedwhiledescending2.25kg(5lb)eachsetuntila
totalloadof2.25kg(5lb)wasreached. Atthe2.25kgload,theparticipantscompletedas
manyrepetitionsaspossibleuntilfailureoruntilatotalof10repetitionswerecompleted.
The total repetitions were documented at the end of every set and aggregated for the
analysis. Therateofperceivedexertionwasmeasuredona1–10scalefrom1(veryeasy)to
10(sohardtheycouldnotcontinue)aftereachsetandaveragedacrossthesessionsforthe
analysis. Followingtheexerciseprotocol,theparticipantsweregivenspecificinstructions
toavoidanyrecoverymethods. Thisincludedtakinganoralanti-inflammatory(ibuprofen,
acetaminophen),takingany“natural”painrelieverssuchasVitaminCorginger,avoiding
theapplicationofanypainreliefcreamandapplyinganyiceorheattothesoreareaaswell
asmassagingorintentionallystretchingthesoremuscle[20,29,30]. Allparticipantswere
requiredtoreturn48haftertheinitialbaselinevisitandallmeasurementswererepeated,
andtheoutcomeswereidenticallymeasured.
2.6. DataAnalysis
AlldatawereanalyzedusingJamovisoftware(Version0.9;Sydney,Australia). The
normality of all data was confirmed using a Shapiro–Wilk test. The statistical analysis
was conducted using a 2 × 2 (Treatment × Time) repeated measures ANOVA with a
Bonferroni–Holmpost-hoctestaswarranted. Forthesignificantmaineffects,anindividual
meanpost-hocanalysiswasperformedaspreviouslyrecommendedbyWeietal.[31]. The
estimatesoftheeffectsizeforthemaineffectswerecalculatedusingetasquared(η2)and
interpretedas0.01=small,0.06=medium,and≥0.14=large[32,33].Ifwarranted,Cohen’s
deffectsizes(d)werecalculatedbetweentheconditionsandinterpretedas0.2=small,
0.5=moderate,and0.8=large[32,33]. Thesignificancewassetatp≤0.05apriori. All
dataarepresentedasamean±standarddeviation(SD).
3. Results
3.1. PerceivedSoreness,ROM,andPlasmaLDHLevels
ThesorenessandmuscledamagemarkersarepresentedinFigure1. Forperceived
soreness(1–10scale;Figure1a),therewasamaineffectfortime(p<0.001;η2=0.715)and
treatment(p=0.011; η2 =0.376). Therewasnointeractionbetweentimeandtreatment
(p=0.171;η2=0.130). Thepost-hocanalysisrevealedthatperceivedsorenesswashigher
fromthebaselineto48hinboththePL(p<0.001;d=1.91)andZEM(p=0.031;d=1.71)
treatments. At48h,perceivedsorenesswaslowerintheZEMgroupcomparedwiththePL
group(p=0.020;d=1.53). ForROM(degrees;Figure1b),therewasamaineffectfortime
(p<0.001;η2=0.890). Nosignificanteffectswereseenfortreatment(p=0.139;η2=0.149).
Furthermore,therewasasignificantinteractionbetweentimeandtreatment(p=0.016;
η2=0.350). ROMdecreasedat48hforboththePL(p<0.001;d=3.14)andZEMgroups
(p<0.001;d=2.01)comparedwiththebaseline. ZEMtreatmentresultedinagreaterROM

## Page 5

Nutraceuticals2021,1 6
at48hcomparedwiththePLgroup(p=0.028;d=1.01). TheanalysisofplasmaLDHlevels
(µmol·mL−1;Figure1c)showedasignificantmaineffectfortime(p<0.019;η2=0.149). No
significantmaineffectswereobservedfortreatment(p<0.638;η2=0.010)orinteraction
betweentimeandtreatment(p<0.721;η2 =0.003). Morespecifically,large-sizedincreases
inLDHactivitywerenotedat48hinboththePL(p=0.039;d=1.03)andZEM(p=0.011;
d=0.81)groups.
Figure 1. Changes in (a) perceived soreness (1–10 scale), (b) range of motion (ROM; degrees), and (c) plasma lactate
dehydrogenase(LDH;µmol·mL−1)fromthebaselineto48hintheplacebo(PL)andZembrin®(ZEM)-treatedgroups.Data
arepresentedasamean±SD.Astatisticalanalysiswasconductedusinga2×2(Treatment×Time)repeatedmeasure
ANOVAwithaBonferroni–Holmpost-hoctest.*indicatesasignificantdifferencefromthebaseline(p<0.05).†indicatesa
significantdifferencefromZEM(p<0.05).
3.2. TotalRepetitions,RPE,andMood
For the total repetitions (Figure 2a), there was a main effect for time (p < 0.001;
η2=0.847)butnotfortreatment(p=0.683;η2=0.012). Moreover,therewasnointeraction
betweentimeandtreatment(p=0.225;η2=0.103). Largedecreasesinthetotalrepetitions
wereobservedforboththePL(p<0.001;d=3.44)andZEM(p<0.001;d=2.27)groups.
The analysis of RPE, as shown in Figure 2b, showed a significant main effect for time
(p=0.008;η2=0.404)butnotfortreatment(p<0.853;η2=0.003). Nointeractionbetween
timeandtreatment(p=0.177;η2=0.126)existed. Morespecifically,RPEoverthesession
washigherat48hcomparedwiththebaselineinthePL(p=0.039;d=1.27)butnotthe
ZEM(p=0.677;d=0.27)group. MoodisshowninFigure2c. Therewasasignificantmain
effectfortime(p=0.043;η2 =0.277)andtreatment(p=0.029;η2 =0.340). Nosignificant
interactionbetweentimeandtreatmentexisted(p=0.155;η2=0.161). Inparticular,mood
wassignificantlyworseat48hcomparedwiththebaselineinthePL(p=0.032;d=1.76)but
notintheZEM(p=0.647;d=0.54)group. Additionally,moodwassignificantlyimproved
intheZEMgroupcomparedwiththePLgroupat48h(p<0.001;d=1.74).

## Page 6

Nutraceuticals2021,1 7
Figure2. Changesin(a)totalrepetitions(repetitions),(b)rateofperceivedexertion(RPE;1–10scale),and(c)profileof
moodstates(POMS;score)fromthebaselineto48hintheplacebo(PL)andZembrin®(ZEM)-treatedgroups. Dataare
presentedasamean±SD.Astatisticalanalysiswasconductedusinga2×2(Treatment×Time)repeatedmeasureANOVA
withaBonferroni–Holmpost-hoctest.*indicatesasignificantdifferencefromthebaseline(p<0.05).†indicatesasignificant
differencefromZEM(p<0.05).Note:amorenegativePOMSscoreindicatesabettermood.
4. Discussion
ZEM has been widely reported to have anxiolytic, anti-depressant, and mild anti-
inflammatoryproperties[3,4,16].Althoughtheseactionsmayhavethepotentialtoproduce
favorable outcomes in response to intense exercise, little to no investigations to date
have studied the possible interactions of ZEM supplementation, muscle soreness, and
performancefollowingunaccustomedintenseexercise. Thus,theaimofthisstudywasto
elucidateifshort-termZEMsupplementationinfluencesmuscledamage,soreness,mood,
andsubsequentexerciseperformancefollowingintense,unaccustomedresistanceexercise.
ThecurrentfindingsshowedthatZEMdecreasedperceivedsorenessandpreservedROM
comparedwiththePLgroupat48hpost-exercise,albeitplasmaLDHlevelsweresimilar
regardlessofthetreatment. ZEMsupplementationalsoresultedinamorefavorableoverall
moodcomparedwiththePLgroupat48h. AlthoughZEMattenuatedincreasesinRPEat
48h,boththeZEMandPLgroupshadaworsenedexerciseperformance. Althoughthe
precisephysiologicalmechanismsresponsiblefortheadvantageousresponseswithZEM
cannotbedelineatedfromthepresentdataalone,thesepreliminaryfindingsmayhave
importantimplicationsinusingZEMinrecoveryfollowingexercise.
Regardless of the treatment, RPE and perceived soreness increased whereas ROM
decreased after 48 h, which supports previous findings using the same unaccustomed
resistanceexerciseprotocol[20,29]. Uniquetothecurrentstudy,perceivedsorenesswas
lowerat48hwithZEMtreatmentversusthePLgroup. Furthermore, RPEwashigher
at48hinthePLgroupwhereasZEMbluntedincreasesinperceptionsofexertion. This
issupportedbypreviousstudiesshowingtheanalgesiceffectsofZEMinrodents,albeit
thecurrentfindingsarethefirsttoourknowledgeindescribingthiseffectinhumans[17].
ROMfollowedasimilarpatterninwhichbothgroupshadlowerROMafter48hbutZEM
partiallyattenuatedlossesinROMversusthePLgroup. Althoughspeculative,thebenefits

## Page 7

Nutraceuticals2021,1 8
ofZEMsupplementationmaybeduetobothphysiologicalandpsychologicalfactors.Loria
etal. showedsimilardecreasesinpainsensitivitybetweenmorphineandZEMinrats[17].
ThisdampeninginpainresponseswithZEMhasbeenpreviouslyattributedtotheinterac-
tionofmesembrinealkaloidswithδ2-andµ-opioidreceptors[8]. Oralopioidtreatment
hasbeenshowntopositivelyinfluencemusculoskeletalpainandfunction(i.e.,ROM)in
olderadults, althoughtheeffectsweresmallinmagnitude[34]. However, itshouldbe
notedthatalong-termopioid/narcoticuseposesconsiderablehealththreatstoconsumers
ofwhichthebenefitsmaynotoutweightherisks. Fromapracticalstandpoint,thecurrent
datashowthatreductionsinperceivedsorenesswerelargeinmagnitude,suggestingZEM
couldserveasapossiblesafeandeffectivealternativeinbluntingmusculoskeletalpain
following exercise. Furthermore, the attenuation in increases in RPE may support that
ZEM can modulate psychophysiological feelings of discomfort of subsequent exercise.
However, the efficacy of ZEM as a pain-altering alternative compared with opioids in
humansiscompletelyunknownandfurthercharacterizationoftheanalgesiceffectsin
humansiswarranted.
Psychologicalalterationstosoreness,RPE,andROMmayhavebeenpreservedwith
ZEMtreatmentduetodecreasesinanxiety. Indeed,previousreportsinpopulationssimilar
to the current one have shown potent anxiolytic effects of ZEM treatment [3,4]. High
levelsofanxietyhavebeenshowntodetrimentallyaffectpainandjointROM[35,36]. For
instance, Kindler et al. showed that anxiety symptoms were associated with joint and
musclehyperalgesiaintemporomandibularjointdisorders[35]. Furthermore,workfrom
ourlabandothershaveshownthatnegativeexpectationsandanxietyleadtodecreased
jointROM[20,36]. Althoughnotconfirmedinthecurrentstudy,thebetteroutcomeswith
ZEMmaybeduetopreviouslyreported5HTreuptakeinhibitormechanisms.5HTreuptake
inhibitorsareacornerstoneofpsychopharmacologicaltherapyforawiderangeofanxiety
disorders[37]. Thisislikelylinkedtoalterationsoftheemotionalstatethroughamygdala
activity [3,38]. For example, Terburg et al. demonstrated a lower amygdala reactivity
andamygdala-hypothalamuscouplinginresponsetofearandemotionaltasksafterZEM
treatment [3]. Paired with current findings, it is plausible that ZEM supplementation
resultedinreducedanxietyandpainanticipation,ultimatelyleadingtoalowerperception
ofsorenessandlossofROM.
Interestingly,thechangesintheperceptiveandfunctionaloutcomesofsorenesswere
not mirrored by the biomarkers of muscle damage. Plasma LDH increased at 48 h in
bothgroupsregardlessofthetreatment. Thissuggeststhatpreviousreportsoftheanti-
inflammatoryeffectsofZEMmaynothaveexistedcurrently[16]. Possibly,thismaybe
duetotheoverallanti-inflammatoryeffectivenessofZEM.Bennetetal. suggestedthat
although ZEM has the ability to partially block inflammatory signaling, this may only
be beneficial in low-grade inflammation [16]. Thus, muscle damage and inflammation
producedbyintenseexerciseinapopulationunaccustomedtoresistancetrainingmay
overwhelmthecapacityofZEMtoexertmeaningfulanti-inflammatoryeffects. Thismay
alsoexplainthelackofergogenicbenefitsofZEM.SimilartoplasmaLDH,therewasno
treatmenteffectonthetotalrepetitionsandbothgroupsperformedworse48hlater. Given
thatmuscledamageleadstocontractiledysfunction[39],ZEMmaynothaveattenuated
performancedecrementsat48hduetotheinabilitytopreventtissuedamage.However,the
readeriscautionedasonlyanindirectmarkerofmuscledamagewasmeasured,currently
necessitatingafuturestudyonhowZEMmayinfluencethedirectmarkersofmyofiber
damageandcontractileperformanceoutcomes. Nonetheless,thelackofergogeniceffects
currentlyaresupportedbypreviousinvestigationsshowingmodesttonoimprovements
insimplereactiontimeandagility[19].
CurrentdataalsoimplicateZEMasamoodstabilizer.Overallmoodwasworseat48h
withthePLtreatmentwhereasZEMpreventedmooddisturbance. Furthermore,mood
wassignificantlybetterat48hcomparedwiththePLgroup. TheworsemoodinthePL
groupissupportedbypreviousinvestigationsshowingthatunaccustomedhighintensity
exerciseresultsinapoorermoodinathletes[40]. Furthermore,previousdescriptionsof

## Page 8

Nutraceuticals2021,1 9
ZEM as a 5HT reuptake and PDE-4 inhibitor support the mood stabilization effects as
bothmechanismshaveimplicationsinthetreatmentforbothdepressionandanxiety[15].
However,ourfindingsareincontrastwithapreviousworkonZEMandmoodduring
exercise[19]. Hoffmanetal. showedthatZEMdidnotaltermoodcomparedwithaPL
groupafter8daysofsupplementation[19]. Althoughtheprecisereasonsforthedisparities
between the findings are not fully clear, they may be due to differences in the study
designandprotocol. Hoffmanetal. didnotincludeanystimuliorinterventionsaimed
atalteringmoodand,thus,therewasnomooddisturbanceforZEMtocounteract. The
highintensityunaccustomedexerciseinthepresentstudyappearedtoexacerbatemood
disturbances,whichmayhaveallowedZEMtohaveagreatereffect. Thisisbolsteredby
previousinvestigationsshowingthat5HTreuptakeinhibition,oneoftheprimaryreported
mechanismsofZEM,improvesdepressivemoodsymptomsmoreeffectivelyinindividuals
withgreaterbaselinemooddisturbances[41]. Thus,ZEMmayserveasaneffectivestrategy
tocombat moodchangesfollowing intenseexercise oractivities whereemotional state
disturbancesareprobable.
AlthoughthecurrentstudyprovidesnovelinformationonthenutraceuticalZembrin®,
andhowitpositivelyaffectspainandmoodresponsesfollowingintenseexercise,there
wereseverallimitations. First,thesamplesizecurrentlyemployedwassmall. Assuch,
these pilot data should be viewed with cautionary optimism with the understanding
that future studies with larger and more diverse samples are needed. However, the
magnitudes of changes in the outcomes due to ZEM supplementation in the present
study were mostly large, which suggests that ZEM has potent effects. All participants
inthecurrentinvestigationwereyoungand healthy. Previousevidence hassuggested
thatZEMandotheragentsthataltermoodmaybemoreeffectiveinindividualswitha
disturbance in basal mood [41]. As such, more investigation is needed to determine if
asimilarbenefitisseeninindividualswithhigherbaselineanxietyormooddisorders.
Althoughsimilarprotocolshavebeendescribedtomeasureperformance[20], onlythe
eccentricexerciserepetitionvolumewascurrentlymeasured. Typicalexerciseregimens
includethecompletionofbothconcentricandeccentricphasesofexercise,whichmaylimit
thepracticalapplicationofthepresentperformancedata. Inconclusion,short-termZEM
treatmentresultsinanattenuationofperceivedsoreness,alossofROM,andanincrease
inRPE48hfollowingunaccustomedresistanceexercise. PlasmaLDHwasunaffectedby
ZEMtreatmentaswasexerciseperformance. However, ZEMtreatmentresultedinthe
preservationofmood48hafterintenseexercise. Thesedatamayproveusefulforathletes
andcompetitorslookingtocombatanyensuingnegativepsychologicaleffectsassociated
withunaccustomedhighintensityexercise.
AuthorContributions:Conceptualization,A.R.B.,H.N.L.,R.R.R.,C.L.B.,T.D.W.andC.G.B.;method-
ology,A.R.B.,H.N.L.,R.R.R.,C.L.B.,T.D.W.andC.G.B.;formalanalysis,R.R.R.andC.G.B.;investiga-
tion,A.R.B.,H.N.L.,R.R.R.,C.L.B.,T.D.W.andC.G.B.;writing—originaldraftpreparation,A.R.B.,
H.N.L.andC.G.B.;writing—reviewandediting,R.R.R.,C.L.B.,T.D.W.andC.G.B.;visualization,
A.R.B.,H.N.L.,R.R.R.,C.L.B.,T.D.W.andC.G.B.;supervision,R.R.R.,C.L.B.,T.D.W.andC.G.B.All
authorshavereadandagreedtothepublishedversionofthemanuscript.
Funding:Thisresearchreceivednoexternalfunding.
InstitutionalReviewBoardStatement:Allexperimentalprocedureswereconductedinaccordance
withtheDeclarationofHelsinkiandapprovedbytheSamfordUniversityInstitutionalReviewBoard
(FULL-HP-21-S-1;August2020).ThedatacollectiontookplacebetweenJanuaryandMay2021.
InformedConsentStatement:Priortoanydatacollection,verbalandwritteninformedconsentwas
obtainedfromeachparticipant.Alltestingwasconductedinourinstitutionalexercisephysiology
laboratoryatSamfordUniversity.
DataAvailabilityStatement:Dataarecontainedandavailablewithinthismanuscript.
Acknowledgments:WewouldliketothankJohnPetrellaforhissupportwiththisproject.

## Page 9

Nutraceuticals2021,1 10
ConflictsofInterest:Theauthorsdeclarenoconflictofinterest.Allresearchwasconductedentirely
independentlyofNutricostInc.oranyofitsconstituents.
References
1. Gericke,O.;Gericke,N.;Stein,D.J.SceletiumTortuosum;AmericanPsychiatricAssociationPublishing:Arlington,VA,USA,2017.
2. Gericke,N.;Viljoen,A.M.Sceletium—Areviewupdate.J.Ethnopharmacol.2008,119,653–663.[CrossRef]
3. Terburg,D.;Syal,S.;Rosenberger,L.A.;Heany,S.;Phillips,N.;Gericke,N.;Stein,D.J.;vanHonk,J.AcuteeffectsofSceletium
tortuosum(Zembrin),adual5-HTreuptakeandPDE4inhibitor,inthehumanamygdalaanditsconnectiontothehypothalamus.
Neuropsychopharmacology2013,38,2708–2716.[CrossRef]
4. Reay,J.;Wetherell,M.A.;Morton,E.;Lillis,J.;Badmaev,V.Sceletiumtortuosum(Zembrin®)amelioratesexperimentallyinduced
anxietyinhealthyvolunteers.Hum.Psychopharmacol.Clin.Exp.2020,35,1–7.[CrossRef]
5. Dimpfel,W.;Gericke,N.;Suliman,S.;Dipah,G.N.C.EffectofZembrin®onBrainElectricalActivityin60OlderSubjectsafter
6WeeksofDailyIntake.AProspective,Randomized,Double-Blind,Placebo-Controlled,3-ArmedStudyinaParallelDesign.
WorldJ.Neurosci.2016,7,140–171.[CrossRef]
6. Hardy,L.Stress,anxietyandperformance.J.Sci.Med.Sport1999,2,227–233.[CrossRef]
7. George,S.Z.;Dover,G.C.;Fillingim,R.B.Fearofpaininfluencesoutcomesafterexercise-induceddelayedonsetmusclesoreness
attheshoulder.Clin.J.Pain2007,23,76–84.[CrossRef]
8. Harvey,A.L.;Young,L.C.;Viljoen,A.M.;Gericke,N.P.PharmacologicalactionsoftheSouthAfricanmedicinalandfunctional
foodplantSceletiumtortuosumanditsprincipalalkaloids.J.Ethnopharmacol.2011,137,1124–1129.[CrossRef][PubMed]
9. Guo,H.;Cheng,Y.;Wang,C.;Wu,J.;Zou,Z.;Niu,B.;Yu,H.;Wang,H.;Xu,J.FFPM,aPDE4inhibitor,reverseslearningand
memorydeficitsinAPP/PS1transgenicmiceviacAMP/PKA/CREBsignalingandanti-inflammatoryeffects.Neuropharmacology
2017,116,260–269.[CrossRef][PubMed]
10. Hirose,R.;Manabe,H.;Yanagawa,K.;Ohshima,E.;Ichimura,M.DifferentialeffectsofPDE4inhibitorsoncorticalneuronsand
T-lymphocytes.J.Pharmacol.Sci.2008,106,310–317.[CrossRef][PubMed]
11. Fujita,M.;Richards,E.M.;Niciu,M.J.;Ionescu,D.F.;Zoghbi,S.S.;Hong,J.;Telu,S.;Hines,C.S.;Pike,V.W.;Zarate,C.A.cAMP
signalinginbrainisdecreasedinunmedicateddepressedpatientsandincreasedbytreatmentwithaselectiveserotoninreuptake
inhibitor.Mol.Psychiatry2017,22,754–759.[CrossRef]
12. Napoletano,M.; Fraire,C.; Santangelo,F.; Moriggi,E.MesembrineIsanInhibitorofPDE4ThatFollowsStructure-Activity
RelationshipofRolipram.2001.Availableonline:https://ssrn.com/abstract=2969480(accessedon16September2021).
13. Coetzee,D.D.;López,V.;Smith,C.High-mesembrineSceletiumextract(Trimesemine™)isamonoaminereleasingagent,rather
thanonlyaselectiveserotoninreuptakeinhibitor.J.Ethnopharmacol.2016,177,111–116.[CrossRef][PubMed]
14. Pringle,A.;Browning,M.;Cowen,P.;Harmer,C.Acognitiveneuropsychologicalmodelofantidepressantdrugaction. Prog.
Neuro-Psychopharmacol.Biol.Psychiatry2011,35,1586–1592.[CrossRef]
15. Cashman,J.R.;Voelker,T.;Johnson,R.;Janowsky,A.Stereoselectiveinhibitionofserotoninre-uptakeandphosphodiesteraseby
dualinhibitorsaspotentialagentsfordepression.Bioorg.Med.Chem.2009,17,337–343.[CrossRef]
16. Bennett,A.C.;Smith,C.ImmunomodulatoryeffectsofSceletiumtortuosum(Trimesemine™)elucidatedinvitro:Implicationsfor
chronicdisease.J.Ethnopharmacol.2018,214,134–140.[CrossRef][PubMed]
17. Loria,M.J.;Ali,Z.;Abe,N.;Sufka,K.J.;Khan,I.A.EffectsofSceletiumtortuosuminrats.J.Ethnopharmacol.2014,155,731–735.
[CrossRef][PubMed]
18. Chiu,S.;Gericke,N.;Farina-Woodbury,M.;Badmaev,V.;Raheb,H.;Terpstra,K.;Antongiorgi,J.;Bureau,Y.;Cernovsky,Z.;Hou,
J.Proof-of-conceptrandomizedcontrolledstudyofcognitioneffectsoftheproprietaryextractsceletiumtortuosum(Zembrin)
targetingphosphodiesterase-4incognitivelyhealthysubjects:ImplicationsforAlzheimer’sdementia.Evid.-BasedComplement.
Altern.Med.2014,2014,682014.[CrossRef]
19. Hoffman,J.R.;Markus,I.;Dubnov-Raz,G.;Gepner,Y.Ergogeniceffectsof8Daysofsceletiumtortuosumsupplementation
onmood,visualtracking,andreactioninrecreationallytrainedmenandwomen. J.StrengthCond. Res. 2020,34,2476–2481.
[CrossRef]
20. McLemore,B.H.;McLemore,S.G.;Rogers,R.R.;Pederson,J.A.;Williams,T.D.;Marshall,M.R.;Ballmann,C.G.NoceboEffects
onPerceivedMuscleSorenessandExercisePerformanceFollowingUnaccustomedResistanceExercise:APilotStudy.J.Funct.
Morphol.Kinesiol.2020,5,40.[CrossRef]
21. Smith,L.L.Causesofdelayedonsetmusclesorenessandtheimpactonathleticperformance:Areview. J.StrengthCond. Res.
1992,6,135–141.
22. Raglin,J.S.Psychologicalfactorsinsportperformance.SportsMed.2001,31,875–890.[CrossRef]
23. Riebe,D.;Ehrman,J.K.;Liguori,G.;Magal,M.ACSM’sGuidelinesforExerciseTestingandPrescription;WoltersKluwer:Riverwood,
IL,USA,2018.
24. Ballmann,C.G.;Maze,S.B.;Wells,A.C.;Marshall,M.M.;Rogers,R.R.Effectsofshort-termRhodiolaRosea(GoldenRootExtract)
supplementationonanaerobicexerciseperformance.J.SportsSci.2019,37,998–1003.[CrossRef]
25. Cui,Y.;Wang,Y.;Liu,G.ProtectiveeffectofBarbaloininaratmodelofmyocardialischemiareperfusioninjurythroughthe
regulationoftheCNPY2-PERKpathway.Int.J.Mol.Med.2019,43,2015–2023.[CrossRef]

## Page 10

Nutraceuticals2021,1 11
26. Ustunova,S.;Takir,S.;Yilmazer,N.;Bulut,H.;Altindirek,D.;Ng,O.H.;Tansel,C.D.;Dogan,B.S.U.;Ozbek,U.;Armutak,E.I.
Hydrogensulphideandnitricoxidecooperateincardioprotectionagainstischemia/reperfusioninjuryinisolatedratheart.In
Vivo2020,34,2507–2516.[CrossRef][PubMed]
27. Grove,J.R.;Prapavessis,H.Preliminaryevidenceforthereliabilityandvalidityofanabbreviatedprofileofmoodstates.Int.J.
SportPsychol.1992,4,45.
28. Covington,A.C.;Rogers,R.R.;Kopec,T.J.;Ballmann,C.G.TheEffectofWalkinganUnfamiliarVersusCompanionDogonMood,
ExerciseEnjoyment,andHeartRate:APilotField.Top.Exerc.Sci.Kinesiol.2021,2,3.
29. Allen,J.D.;Mattacola,C.G.;Perrin,D.H.Effectofmicrocurrentstimulationondelayed-onsetmusclesoreness:Adouble-blind
comparison.J.Athl.Train.1999,34,334.[PubMed]
30. Connolly,D.A.;Sayers,S.P.;McHugh,M.P.Treatmentandpreventionofdelayedonsetmusclesoreness.J.StrengthCond.Res.
2003,17,197–208.
31. Wei,J.;Carroll,R.J.;Harden,K.K.;Wu,G.Comparisonsoftreatmentmeanswhenfactorsdonotinteractintwo-factorialstudies.
AminoAcids2012,42,2031–2035.[CrossRef][PubMed]
32. Fritz,C.O.;Morris,P.E.;Richler,J.J.Effectsizeestimates:Currentuse,calculations,andinterpretation.J.Exp.Psychol.Gen.2012,
141,2–18.[CrossRef]
33. Cohen,J.StatisticalPowerAnalysisfortheBehavioralSciences,2nded.;ErlbaumAssociates:Hillsdale,MI,USA,1988.
34. Megale,R.Z.;Deveza,L.A.;Blyth,F.M.;Naganathan,V.;Ferreira,P.H.;McLachlan,A.J.;Ferreira,M.L.Efficacyandsafetyof
oralandtransdermalopioidanalgesicsformusculoskeletalpaininolderadults:Asystematicreviewofrandomized,placebo-
controlledtrials.J.Pain2018,19,475.e1–475.e24.[CrossRef]
35. Kindler,S.;Samietz,S.;Houshmand,M.;Grabe,H.J.;Bernhardt,O.;Biffar,R.;Kocher,T.;Meyer,G.;Völzke,H.;Metelmann,H.-R.
Depressiveandanxietysymptomsasriskfactorsfortemporomandibularjointpain:Aprospectivecohortstudyinthegeneral
population.J.Pain2012,13,1188–1197.[CrossRef][PubMed]
36. Hernandez-Reif,M.;Field,T.;Krasnegor,J.;Theakston,H.Lowerbackpainisreducedandrangeofmotionincreasedafter
massagetherapy.Int.J.Neurosci.2001,106,131–145.[CrossRef][PubMed]
37. Kent,J.M.;Coplan,J.D.;Gorman,J.M.Clinicalutilityoftheselectiveserotoninreuptakeinhibitorsinthespectrumofanxiety.Biol.
Psychiatry1998,44,812–824.[CrossRef]
38. Izumi,T.;Kitaichi,Y.;An,Y.;Inoue,T.;Yoshioka,M.TheAmygdalaIstheTargetBrainSiteofAnxiolyticEffectsofSSRIs;Nova
BiomedicalBooks:Hauppauge,NY,USA,2018.
39. Peñailillo,L.;Blazevich,A.;Numazawa,H.;Nosaka,K.Rateofforcedevelopmentasameasureofmuscledamage.Scand.J.Med.
Sci.Sports2015,25,417–427.[CrossRef][PubMed]
40. Morgan,W.P.;Costill,D.L.;Flynn,M.G.;Raglin,J.S.;O’Connor,P.J.Mooddisturbancefollowingincreasedtraininginswimmers.
Med.Sci.SportsExerc.1988,44,125.[CrossRef]
41. Hieronymus,F.;Lisinski,A.;Nilsson,S.;Eriksson,E.InfluenceofbaselineseverityontheeffectsofSSRIsindepression: An
item-based,patient-levelpost-hocanalysis.LancetPsychiatry2019,6,745–752.[CrossRef]

